Lupin Share Price | Lupin Stock Screener
LUPIN
Pharmaceuticals
Share Price NSE
₹2281.80
▼
-2.70 (-0.12%)
Share Price BSE
₹2279.50
▼
-5.85 (-0.26%)
As of May 22, 2026, the Lupin share price (NSE: LUPIN) is ₹2,281.80 on NSE and ₹2,279.50 on BSE, down 0.12% from the previous close, with shares trading between ₹2,270.00 and ₹2,304.50, and a 52-week range of ₹1,851.80–₹2,460.10.
Check LUPIN 52-week high low for the annual price range and momentum.
Use the Lupin stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Lupin Market Cap
₹102,944.41 Cr.
LUPIN P/E Ratio (TTM)
19.41
Lupin P/B Ratio
4.63
EPS (TTM)
₹128.45
Dividend Yield
0.79%
Debt to Equity
0.27
LUPIN 52 Week High
₹2460.10
Lupin 52 Week Low
₹1851.80
Operating Margin
31.00%
Profit Margin
19.50%
LUPIN Revenue (TTM)
₹7,533.00
EBITDA
₹2,412.00
Net Income
₹1,469.00
Total Assets
₹38,365.00
Total Equity
₹22,448.00
Lupin Share Price Chart
Screen Lupin share price with an interactive chart. Analyse LUPIN price trends and volatility across different timeframes.
Lupin Company Profile - Fundamental Screener
Screen Lupin company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for LUPIN shares.
Lupin is a global pharmaceutical company producing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. Founded in 1983, it operates in over 100 markets, specializing in cardiovascular, diabetology, asthma, pediatric, central nervous system, gastrointestinal, anti-infective, and NSAID therapies. Lupin is a leader in anti-TB and cephalosporins segments. The...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
M D Gupta
ISIN
INE326A01037
Website
https://www.lupin.com/
Lupin Balance Sheet Screener
Screen LUPIN balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 38,365 | 29,205 | 23,997 | 22,956 | 21,821 | 23,610 | 24,984 | 27,949 | 26,305 | 26,607 |
| Current Assets | 24,027 | 16,799 | 13,448 | 12,451 | 12,458 | 13,986 | 15,413 | 13,854 | 12,210 | 11,953 |
| Fixed Assets | 9,352 | 9,719 | 8,878 | 8,355 | 7,382 | 7,881 | 7,938 | 11,087 | 10,362 | 11,033 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 3,200 | 2,949 | 1,122 | 1,148 | 1,101 | 1,316 | 3,178 | 8,030 | 7,593 | 6,955 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 22,448 | 17,294 | 14,374 | 12,543 | 12,222 | 13,858 | 12,581 | 13,789 | 13,617 | 13,532 |
| Share Capital | 91 | 91 | 91 | 91 | 91 | 91 | 91 | 91 | 90 | 90 |
| Reserves & Surplus | 22,357 | 17,112 | 14,199 | 12,374 | 12,062 | 13,712 | 12,446 | 13,652 | 13,487 | 13,407 |
Lupin Income Statement Screener - Profit & Revenue Analysis
Screen Lupin income statement and profit fundamentals.
Analyze LUPIN quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Lupin share price evaluation.
| Item | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7,533 | 7,215 | 6,921 | 6,243 | 5,619 | 5,672 | 5,539 | 5,582 | 4,924 | 5,109 | 4,980 | 4,765 | 4,368 | 4,263 | 4,106 |
| Expenses | 5,120 | 5,332 | 4,706 | 4,541 | 4,346 | 4,412 | 4,332 | 4,359 | 3,964 | 4,160 | 4,121 | 3,958 | 3,852 | 3,790 | 3,693 |
| EBITDA | 2,412 | 1,883 | 2,215 | 1,702 | 1,273 | 1,261 | 1,207 | 1,223 | 960 | 950 | 859 | 807 | 515 | 473 | 414 |
| Operating Profit % | 31.00% | 25.00% | 31.00% | 26.00% | 22.00% | 21.00% | 21.00% | 21.00% | 19.00% | 18.00% | 17.00% | 17.00% | 11.00% | 11.00% | 10.00% |
| Depreciation | 447 | 313 | 317 | 299 | 393 | 272 | 257 | 248 | 457 | 257 | 248 | 235 | 264 | 220 | 204 |
| Interest | 120 | 115 | 108 | 92 | 89 | 67 | 71 | 68 | 71 | 74 | 81 | 86 | 93 | 84 | 55 |
| Profit Before Tax | 1,928 | 1,522 | 2,007 | 1,416 | 896 | 1,071 | 1,055 | 993 | 498 | 736 | 630 | 559 | 259 | 246 | 210 |
| Tax | 459 | 342 | 522 | 194 | 114 | 212 | 195 | 188 | 130 | 117 | 134 | 106 | 16 | 89 | 75 |
| Net Profit | 1,469 | 1,181 | 1,485 | 1,222 | 782 | 859 | 860 | 806 | 368 | 619 | 495 | 453 | 242 | 158 | 135 |
| EPS | 34.83 | 25.74 | 32.36 | 26.70 | 16.93 | 18.75 | 18.70 | 17.58 | 7.89 | 13.47 | 10.76 | 9.94 | 5.19 | 3.38 | 2.85 |
Lupin Cash Flow Screener - Liquidity Fundamentals
Screen LUPIN cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 3,000 | 3,648 | 1,897 | 367 | 1,822 | 1,469 | 1,666 | 1,751 | 4,114 | -382 |
| Investing Activities | -4,172 | -1,712 | -1,287 | 1,292 | -1,240 | 1,107 | -3,283 | 470 | -2,527 | -6,769 |
| Financing Activities | 1,732 | -2,184 | -337 | -1,572 | -1,885 | -891 | 744 | -1,492 | 433 | 5,836 |
| Net Cash Flow | 560 | -248 | 273 | 87 | -1,303 | 1,685 | -872 | 729 | 2,019 | -1,315 |
Lupin Shareholding Pattern Screener
See Lupin shareholding pattern with promoter, FII, and DII holdings.
Check Lupin promoter holding and ownership changes for LUPIN on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 46.86% | 46.92% | 46.90% | 46.90% | 46.89% | 47.01% | 46.98% | 46.96% |
| FII Holding | 21.71% | 21.46% | 21.25% | 20.49% | 21.49% | 18.28% | 19.32% | 21.50% |
| DII Holding | 25.32% | 25.41% | 25.56% | 26.55% | 25.58% | 27.76% | 26.78% | 25.09% |
| Govt Holding | 0.00% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public Holding | 5.05% | 5.10% | 5.23% | 5.12% | 5.10% | 5.70% | 5.65% | 5.29% |
| Other Holding | 1.06% | 1.10% | 1.05% | 0.94% | 0.93% | 1.23% | 1.26% | 1.15% |
| Shareholder Count | 290,411 | 283,210 | 286,604 | 280,256 | 288,931 | 280,248 | 288,537 | 279,280 |
Lupin Share Dividend Screener - Share Yield Analysis
Check Lupin dividend history with payout and yield data.
View Lupin dividend details including ex-dates and amounts for LUPIN stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹12.00 | 0.52% |
| 2024-March | ₹8.00 | 0.39% |
| 2023-March | ₹4.00 | 0.25% |
| 2022-March | ₹4.00 | 0.61% |
| 2021-March | ₹6.50 | 0.87% |
| 2020-March | ₹6.00 | 0.59% |
| 2019-March | ₹5.00 | 0.85% |
| 2018-March | ₹5.00 | 0.68% |
| 2017-March | ₹7.50 | 1.02% |
Lupin Stock Index Membership
See which indices include Lupin stock.
Check LUPIN index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE 200 EQUAL WEIGHT
BSE INDEX BSE HC
BSE INDEX BSE100
BSE INDEX BSE200
BSE INDEX BSE500
BSE INDEX BSEMOI
BSE INDEX DOL100
BSE INDEX ESG100
BSE INDEX LMI250
BSE INDEX MID150
BSE INDEX MIDCAP
BSE INDEX MIDSEL
BSE INDEX MSL400
BSE INDEX SNXT50
NIFTY 200
NIFTY 500
NIFTY ALPHA 50
NIFTY ALPHALOWVOL
NIFTY HEALTHCARE
NIFTY INDIA MFG
NIFTY LARGEMID250
NIFTY LOW VOLATILITY 50
NIFTY MID LIQ 15
NIFTY MIDCAP 100
NIFTY MIDCAP 150
NIFTY MIDCAP 50
NIFTY MIDCAP SELECT (MIDCPNIFTY)
NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY MULTI MFG
NIFTY PHARMA
NIFTY SHARIAH 25
NIFTY TOTAL MKT
NIFTY200 ALPHA 30
NIFTY200MOMENTM30
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MOMENTUM 50
NIFTY500 MULTICAP
NIFTY500 SHARIAH
NIFTYM150MOMNTM50
Lupin Market Events Screener - Corporate Actions
Get Lupin corporate actions including splits, bonuses, and buybacks.
Check Lupin stock events that may affect LUPIN share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-05-07 | 2026-05-07 | Quarterly Result Announcement | NA | 5.68% |
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | 2.72% |
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | 2.76% |
| 2025-08-11 | 2025-08-11 | Annual General Meeting | NA | 1.23% |
| 2025-08-05 | 2025-08-05 | Quarterly Result Announcement | NA | -2.52% |
| 2025-07-25 | 2025-07-25 | Dividend | ₹ 12.00 /share | -5.80% |
| 2025-05-14 | 2025-05-14 | Quarterly Result Announcement | NA | -2.12% |
| 2025-02-11 | 2025-02-11 | Quarterly Result Announcement | NA | 1.65% |
| 2024-11-07 | 2024-11-07 | Quarterly Result Announcement | NA | 0.66% |
| 2024-08-02 | 2024-08-02 | Annual General Meeting | NA | 9.82% |
| 2024-07-16 | 2024-07-16 | Dividend | ₹ 8.00 /share | 10.68% |
| 2023-07-14 | 2023-07-14 | Dividend | ₹ 4.00 /share | 27.11% |
| 2022-07-14 | 2022-07-15 | Dividend | ₹ 4.00 /share | -5.87% |
| 2021-07-27 | 2021-07-28 | Dividend | ₹ 6.50 /share | -8.30% |
Lupin Competitors Screener - Peer Comparison
Screen LUPIN competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 457,265 | 41.18 | 54,729 | 9.71% | 10,980 | 67.81 |
| Divis Laboratories | 181,448 | 72.40 | 9,712 | 18.67% | 2,191 | 66.76 |
| Torrent Pharmaceuticals | 148,703 | 65.64 | 11,539 | 6.99% | 1,911 | 57.60 |
| Cipla | 115,206 | 29.94 | 27,712 | -2.46% | 3,783 | 68.41 |
| Dr Reddys Laboratories | 111,108 | 26.84 | 33,593 | -0.44% | 3,998 | 58.65 |
| Mankind Pharma | 103,024 | 57.32 | 12,744 | 20.90% | 2,007 | 72.21 |
| Lupin | 102,944 | 19.41 | 27,488 | 19.98% | 5,345 | 43.67 |
| Zydus Life Science | 99,728 | 20.25 | 23,511 | 18.55% | 4,615 | 63.02 |
| Aurobindo Pharma | 87,149 | 25.19 | 32,346 | 9.43% | 3,484 | 69.63 |
| Laurus Labs | 71,655 | 80.32 | 6,813 | 21.03% | 884 | 80.55 |
Lupin Company Announcements - News Screener
Screen LUPIN latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| Announcement under Regulation 30 (LODR)-Press Release / Media Release | - | |
| 2026-05-21 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-05-20 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-05-19 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-05-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-14 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-05-07 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-05-07 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-05-07 | Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s | - |
| 2026-05-07 | Corporate Action-Board approves Dividend | - |
| 2026-05-07 | Board Meeting Outcome for The Audited Financial Results For The Quarter And Year Ended March 31 2026 And Recommendation Of Final Dividend Of Rs. 18 /- Per Equity Share I.E. 900 % Of The Face Value Of Rs. 2/- Each Fully Paid Up For The Financial Year Ended | - |
| 2026-05-07 | Approval Of The Audited Financial Statements For The Quarter And Year Ended March 31 2026 And Recommend Final Dividend Of Rs. 18/- Per Equity Share I.E. 900% Of The Face Value Of Rs. 2/- Each Fully Paid Up For The Financial Year Ended March 31 2026 | - |
| 2026-05-05 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-05-05 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-05-04 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-04-23 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-04-22 | Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31 2026 And Recommend Dividend If Any. | - |
| 2026-04-22 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-04-18 | U.S. FDA Has Concluded An Inspection At The Companys Manufacturing Facility Located In Somerset New Jersey U.S.A. | - |
| 2026-04-17 | Announcement under Regulation 30 (LODR)-Acquisition | - |